

Date and Time: *Monday 21st and Tuesday 22nd July 2014*
10:00 – 16:30

Minutes: Draft

Guideline Development Group Meeting **Diabetes in children and young people guideline update**

Place: *Royal College of Obstetricians and Gynaecologists
London*

Present:

Jerry Wales (Chair) (JW)	(Present for notes 1 – 17)
Francesca Annan (FA)	(Present for notes 1 – 17)
Jo Dalton (JD)	(Present for notes 1 – 17)
Jacqui Double (JDo)	(Present for notes 1 – 17)
Sarah Eaton (SE)	(Present for notes 1 – 17)
Julie Edge (JE)	(Present for notes 1 – 17)
Nikhil Gokani (NG)	(Present for notes 1 – 17)
William Lamb (WL)	(Present for notes 1 – 17)
Carol Metcalfe (CM)	(Present for notes 1 – 17)

In attendance:

NCC-WCH staff: Yelan Guo (YG) Juliet Kenny (JK) Paul Jacklin (PJ) Sadia Janjua (SJ) Moirra Mugglestone (MM) Stephen Murphy (SM) Amy Wang (AW)		(Present for notes 11 – 12) (Present for notes 1 – 17) (Present for note 5) (Present for notes 1 – 12) (Present for notes 1 – 17) (Present for notes 1 – 17) (Present for notes 8 – 9 and 11 – 12)
NICE attendees: Oliver Bailey James Hall		(Present for notes 1 – 17) (Present for notes 1 – 17)

Observers:

None		
------	--	--

Notes

Day 1

1. JW welcomed the group to day 1 of the eleventh meeting of this guideline development group (GDG). Apologies were received from Zosia Beckles.
2. JW explained that AW's arrival had been delayed and therefore the agenda had been rearranged to accommodate this.
3. The minutes from GDG 10 were agreed.
4. JW asked all the GDG members and other attendees to declare any new interests that they had accrued since GDG 10 and reiterate any interests declared previously that were relevant to the meeting agenda.

JD

Personal non-pecuniary interest

Attended a study day funded by Medtronic on a topic that is not specific to the guideline scope (continuous subcutaneous insulin infusion therapy).

No other declarations of interest were received from the GDG members or the other attendees. It was agreed that no interests declared at the meeting or previously warranted exclusion of any GDG members from discussions of evidence or formulation of recommendations at the meeting

5. PJ updated the group on progress with the health economics analysis for the topic of multiple daily injections versus mixed insulin in children and young people with type 1 diabetes. The IMS Core Diabetes Model was demonstrated live on screen and the group had the opportunity to ask questions and provide feedback.
6. JE gave a brief clinical introduction to the management of diabetic ketoacidosis (DKA) and summarised the deliberations of the DKA subgroup regarding the evidence reviewed for the DKA section of the guideline.
7. JE began leading the group through the process of ratifying the new recommendations for children and young people with DKA including agreeing editorial changes to the wording of recommendations that had arisen since the final DKA subgroup meeting through the NICE editorial process.
8. AW arrived and presented the evidence for the management of cerebral oedema in children and young people with DKA. The group discussed the findings of the review.
9. JE led the group through the process of interpreting the evidence and drafting recommendations for the management of cerebral oedema in children and young people with DKA. Notes were made live on screen.
10. JE resumed leading the group through the process of ratifying the new recommendations for children and young people with DKA including agreeing editorial changes to the wording of recommendations that had arisen since the final DKA subgroup meeting through the NICE editorial process.
11. JH gave a presentation on the role of the NICE editor and the products developed by NICE.
12. JK gave a brief verbal description of the full guideline care pathway including its format and how it differs from and contributes to the NICE digital pathway.

Day 2

13. JW welcomed the group to day 2 of the meeting.
14. JW led the group through the process of agreeing the content of the new and updated recommendations for children and young people with type 1 diabetes.
15. JW led the group through the process of agreeing the content of the new and updated recommendations for children and young people with type 2 diabetes.
16. MM outlined next steps including the aims of the next GDG meeting and the processes being undertaken by the technical team and NICE (led by JW and SM) to check and amend the recommendations from the 2004 guideline that were not covered by the update scope.
17. There were no items of other business. JW thanked the group for attending and closed the meeting.

Date, time and venue of the next meeting

Tuesday 9th and Wednesday 10th September 10:00–16:30 at the Royal College of Obstetricians and Gynaecologists, London